Skip to main content

Crescent Biopharma, Inc 8-K, filed Nov 12, 2026

Crescent Biopharma, Inc. (CBIO)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 12, 2026

About this 8-K

Crescent Biopharma, Inc filed this 8-K on November 12, 2026.

Crescent Biopharma completed Phase 1/2 ASCEND dose escalation after dosing more than 125 patients and plans initial CR-001 monotherapy data in Q1 2027. Cash was $289.4 million as of September 30, 2026, funding operations into the second half of 2028. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits